Study guide

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis

Key Takeaways Explain This Topic AI

Primary amenorrhea is no menses by age 15 (or by 13 without breast development); Mullerian agenesis has normal breasts and pubic hair, while androgen insensitivity has breasts but scant pubic hair and a 46,XY karyotype.

Secondary amenorrhea is evaluated with a pregnancy test first, then TSH, prolactin and FSH, then a progestin challenge or estrogen status.

Heavy menstrual bleeding since menarche in an adolescent suggests von Willebrand disease; anovulatory bleeding from an immature HPA axis is common in the first years after menarche.

Letrozole is first-line ovulation induction in PCOS; infertility is evaluated after 12 months (6 months if 35 or older) with semen analysis, ovulation testing and tubal patency.

Women with a uterus who take estrogen for menopausal symptoms need a progestin to prevent endometrial hyperplasia; HRT is avoided with breast cancer, VTE, active liver disease and unexplained bleeding.

Last updated: October 2026

Why this area matters

TOS area Q asks you to:

explain the actions of female hormones, the onset of puberty and the menstrual cycle, secondary sex characteristics and breast development;

  • recognize amenorrhea and infertility;
  • diagnose disorders of later life such as osteoporosis ;

plan treatment, including hormone therapy and bisphosphonates , with their side effects.

TOS area S covers menstrual disorders:

  • amenorrhea;
  • abnormal uterine bleeding, endometrial polyps and endometrial hyperplasia ;
  • bleeding from an immature hypothalamic-pituitary-ovarian (HPO) axis ;
  • drug-induced bleeding;

blood dyscrasias .

Menstrual complaints are among the most common gynecologic consultations, and infertility affects a substantial minority of Filipino couples.

Menstrual Cycle Physiology

The normal menstrual cycle has an average duration of 28 days (normal range 21 to 35 days) and reflects coordinated neuroendocrine feedback between the hypothalamus, anterior pituitary gland, and ovaries (the HPO axis).

Ovarian and Endometrial Cycles

The Follicular (Proliferative) Phase:

Days 1 to 14: Pulsatile gonadotropin-releasing hormone (GnRH) from the arcuate nucleus of the hypothalamus stimulates anterior pituitary secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

FSH recruits a cohort of antral follicles. Under FSH stimulation, granulosa cells express aromatase, converting theca-cell-derived androgens into Estradiol ( E 2 E_2 E 2 ​ ) .

The follicle with the highest aromatase activity and FSH receptor density becomes the dominant follicle (Graafian follicle). Rising estradiol induces the proliferative phase of the endometrium, promoting glandular mitosis and elongation of spiral arteries.

The LH Surge: As circulating estradiol levels exceed 200 pg/mL for at least 48 hours, feedback on the pituitary switches from negative to positive feedback. This triggers a massive mid-cycle LH surge . The LH surge induces resumption and completion of meiosis I (arrested in prophase I since fetal life) with extrusion of the first polar body; the oocyte then arrests in metaphase II until fertilization. Ovulation occurs 24 to 36 hours after the onset of the LH surge (or 10 to 12 hours after its peak).

The Luteal (Secretory) Phase:

Days 14 to 28: The ruptured Graafian follicle transforms into the Corpus Luteum , which produces copious Progesterone and moderate estradiol.

Progesterone converts the proliferative endometrium into the secretory endometrium , characterized by tortuous glycogen-rich glands and stromal decidualization, preparing for blastocyst implantation.

The luteal phase is relatively constant at about 14 days , so variation in cycle length comes mainly from the follicular phase. In the absence of human chorionic gonadotropin (hCG) from an implanting blastocyst, the corpus luteum undergoes luteolysis, degenerating into the fibrous corpus albicans .

Menstruation: Abrupt withdrawal of progesterone and estradiol triggers intense vasospasm of the endometrial spiral arterioles, causing ischemic necrosis, lysosomal enzyme release, and shedding of the functional layer of the endometrium ( stratum functionale ).

Abnormal Uterine Bleeding (AUB) — The FIGO PALM-COEIN Classification

Abnormal Uterine Bleeding in non-gestational reproductive-aged women is categorized by the International Federation of Gynecology and Obstetrics (FIGO) into structural and non-structural etiologies:

PALM: Structural Etiologies (Identified via Imaging or Histopathology)

P - Polyp (AUB-P): Benign endometrial or endocervical overgrowths of stroma and blood vessels. Diagnosed via saline infusion sonohysterography (SIS) or hysteroscopy; treated with hysteroscopic polypectomy.

A - Adenomyosis (AUB-A): Ectopic presence of endometrial glands and stroma within the myometrium, accompanied by reactive smooth muscle hypertrophy. Classically presents in multiparous women in their 40s with heavy menstrual bleeding and severe secondary dysmenorrhea. Pelvic exam reveals a globular, symmetrically enlarged, soft, boggy, and tender uterus .

L - Leiomyoma (AUB-L / Uterine Fibroids): Benign monoclonal smooth muscle neoplasms. Subclassified by location: submucosal (most strongly linked to heavy bleeding and recurrent pregnancy loss), intramural (most common overall), and subserosal (often asymptomatic or causing urinary/rectal bulk symptoms).

M - Malignancy & Hyperplasia (AUB-M): Endometrial atypical hyperplasia / endometrial intraepithelial neoplasia (EIN) and endometrial carcinoma. Postmenopausal bleeding is the cardinal symptom.

COEIN: Non-Structural Etiologies (Systemic or Functional)

C - Coagulopathy (AUB-C): Systemic disorders of hemostasis, most commonly von Willebrand disease (suspected in young adolescents presenting with heavy menstrual bleeding since menarche).

O - Ovulatory Dysfunction (AUB-O): Characterized by unpredictable, irregular bleeding without mid-cycle ovulatory symptoms. Chronic anovulation leads to continuous unopposed estrogen stimulation without cyclical progesterone secretion; the endometrium proliferates excessively until it outgrows its vascular supply and breaks down irregularly. Classic causes: Polycystic Ovary Syndrome (PCOS), hypothyroidism, hyperprolactinemia, anorexia, and perimenopause.

E - Endometrial (AUB-E): Primary localized dysregulation of endometrial hemostatic mechanisms (e.g., deficiency of local vasoconstrictors like endothelin-1 or excess of prostaglandins like P G E 2 PGE_2 PG E 2 ​ ).

I - Iatrogenic (AUB-I): Unscheduled bleeding secondary to intrauterine devices (copper IUD or LNG-IUD), systemic hormones, psychotropic drugs, or anticoagulants.

N - Not Otherwise Classified (AUB-N): Rare entities such as arteriovenous malformations or myometrial hypertrophy.

Polycystic Ovary Syndrome (PCOS)

PCOS (Stein-Leventhal syndrome) is the most common endocrinopathy among reproductive-aged women, affecting 6% to 12% of females.

Diagnostic Criteria: The Rotterdam Criteria require at least 2 of the following 3 features after excluding secondary causes (such as congenital adrenal hyperplasia, Cushing syndrome, and androgen-secreting tumors):

Oligo- or Anovulation: Infrequent menses ( < 9 cycles/year < 9\text{ cycles/year} < 9 cycles/year ) or amenorrhea.

Hyperandrogenism: Clinical (hirsutism assessed by Ferriman-Gallwey score, severe cystic acne, androgenic alopecia) or biochemical (elevated total/free testosterone, elevated DHEAS).

Polycystic Ovarian Morphology on Ultrasound: Presence of ≥ 20 \ge 20 ≥ 20 follicles per ovary measuring 2 to 9 mm in diameter, or an increased ovarian volume ≥ 10 mL \ge 10\text{ mL} ≥ 10 mL (" string of pearls " appearance).

Neuroendocrine and Metabolic Pathophysiology:

Accelerated GnRH pulsatility drives preferential pituitary LH secretion, leading to an elevated LH:FSH ratio (characteristically > 2 : 1 > 2:1 > 2 : 1 or > 3 : 1 > 3:1 > 3 : 1 ) .

Excessive LH acts on ovarian theca cells to upregulate CYP17, overproducing androgens (androstenedione and testosterone).

Deficient FSH prevents aromatization to estrogen in granulosa cells, arresting follicle maturation.

Peripheral conversion of androgens in adipose tissue yields excess Estrone ( E 1 E_1 E 1 ​ ) , maintaining chronic anovulation.

Insulin Resistance: Peripheral insulin resistance with compensatory hyperinsulinemia is present in up to 80% of patients. Hyperinsulinemia directly stimulates theca cell androgen production and suppresses liver synthesis of Sex Hormone-Binding Globulin (SHBG) , dramatically increasing bioavailable free testosterone.

Long-term Health Risks: Endometrial adenocarcinoma (a 3- to 5-fold increased risk due to continuous, chronic unopposed estrogen driving endometrial hyperplasia without progesterone-induced secretory differentiation and shedding), Type 2 Diabetes Mellitus, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), and cardiovascular disease.

Management:

Lifestyle Modification: 5% to 10% weight loss restores ovulatory cycles and improves insulin sensitivity.

Combined Oral Contraceptives (COCs): First-line for cycle regulation and hirsutism in patients not desiring pregnancy (suppresses LH, increases hepatic SHBG, reduces free testosterone).

Metformin: Enhances insulin sensitivity and reduces hyperandrogenemia.

Spironolactone: Anti-androgen competitive aldosterone receptor antagonist; treats persistent hirsutism (teratogenic; requires concurrent contraception).

Ovulation Induction for Infertility: Letrozole (aromatase inhibitor) is the first-line agent for ovulation induction in PCOS (demonstrating higher live birth rates than clomiphene citrate).

Puberty

Usual sequence: thelarche (breast budding, about age 8 to 13), then pubarche (pubic hair), then the growth spurt , then menarche , about 2 to 3 years after thelarche.

Tanner stages grade breast and pubic hair development.

Precocious puberty: signs before age 8 in girls.

Central (GnRH-dependent) precocious puberty is usually idiopathic in girls and is treated with GnRH agonists.

Peripheral precocious puberty has causes such as ovarian tumors, McCune-Albright syndrome, congenital adrenal hyperplasia and exogenous estrogen.

Delayed puberty: no breast development by age 13.

Abnormal bleeding in adolescents and from drugs or blood disorders

Immature HPO axis: in the first 1 to 2 years after menarche, cycles are often anovulatory . Unopposed estrogen then causes irregular, sometimes heavy bleeding.

Treatment: iron, NSAIDs or tranexamic acid, and cyclic progestins or combined pills.

Severe bleeding: high-dose estrogen or combined pills to stabilize the endometrium.

Blood dyscrasias: von Willebrand disease (the most common inherited bleeding disorder), platelet disorders, leukemia, aplastic anemia and dengue thrombocytopenia.

Suspect them with heavy bleeding since menarche , PPH, bleeding after dental extraction or surgery, or a family history.

Drug-induced bleeding:

  • anticoagulants;
  • antipsychotics and other drugs that raise prolactin ;
  • hormonal contraceptives (breakthrough bleeding);
  • tamoxifen (polyps, hyperplasia);

herbal estrogens.

Rule out first: in any reproductive-age woman with abnormal bleeding, exclude pregnancy and pregnancy complications before anything else.

Amenorrhea

Primary amenorrhea: no menses by 15 years , or by 13 without breast development.

Cause Breasts Uterus Key feature

Mullerian agenesis (MRKH) Normal Absent 46,XX; normal ovaries and pubic hair; renal anomalies; neovagina by dilators or surgery

Androgen insensitivity Normal Absent 46,XY; testes in abdomen or groin (remove after puberty, because of the cancer risk); scant pubic and axillary hair

  • Turner syndrome (45,X) Absent Present Short stature, webbed neck, streak gonads, high FSH ; coarctation
  • Kallmann syndrome Absent Present Low GnRH, anosmia , low FSH/LH
  • Imperforate hymen or transverse septum Normal Present Cyclic pain, hematocolpos , bulging membrane
  • Constitutional delay Delayed Present Family history; normal eventual puberty

Secondary amenorrhea: no menses for 3 months in a woman with previously regular cycles, or 6 months if irregular.

Pregnancy test first.

TSH and prolactin.

FSH and estradiol , with a progestin challenge or an assessment of estrogen status.

Causes of secondary amenorrhea:

hypothalamic : stress, weight loss, eating disorders, excessive exercise; low FSH and estrogen; bone loss;

hyperprolactinemia : prolactinoma, drugs, hypothyroidism; galactorrhea; treated with cabergoline or bromocriptine ;

  • PCOS ;
  • primary ovarian insufficiency : loss of ovarian function before 40, high FSH;
  • Sheehan syndrome ;

Asherman syndrome : intrauterine adhesions after curettage or TB, with a normal hormone profile and no bleeding after an estrogen-progestin challenge.

Dysmenorrhea and premenstrual disorders

Primary dysmenorrhea:

  • painful menses caused by prostaglandins , without pelvic disease;
  • begins within 1 to 2 years of menarche;

treated with NSAIDs started at the onset of pain, or hormonal contraceptives.

Secondary dysmenorrhea: suggests endometriosis, adenomyosis, fibroids or PID.

Premenstrual syndrome and premenstrual dysphoric disorder: symptoms in the luteal phase that resolve after menses. Treated with lifestyle measures, SSRIs or combined pills.

Infertility

Definition: no pregnancy after 12 months of regular unprotected intercourse, or 6 months if the woman is 35 or older .

Causes:

  • male factor (about a third);
  • ovulatory disorders (PCOS, hypothalamic, thyroid, prolactin);
  • tubal factor (PID, genital TB, endometriosis, previous surgery);
  • uterine factors;

unexplained.

Evaluation:

  • semen analysis ;
  • ovulation : menstrual history and mid-luteal progesterone ;
  • ovarian reserve : AMH, antral follicle count, day-3 FSH;

tubal patency : hysterosalpingography or laparoscopy with dye.

Treatment:

  • ovulation induction with letrozole (first-line in PCOS) or clomiphene ;
  • intrauterine insemination;

IVF for tubal disease, severe male factor or failed treatment.

Ovarian stimulation risks ovarian hyperstimulation syndrome (enlarged ovaries, ascites, hemoconcentration, thrombosis) and multiple pregnancy.

Menopause, hormone therapy and osteoporosis

Definition: menopause is 12 months of amenorrhea , at an average age of about 50 to 51 .

The perimenopause has irregular cycles and rising FSH.

Premature menopause occurs before 40.

Symptoms:

  • vasomotor : hot flushes and night sweats;
  • sleep and mood changes;
  • genitourinary syndrome of menopause : vaginal dryness, dyspareunia, urgency, recurrent UTI;

accelerated bone loss and rising cardiovascular risk.

Hormone therapy (HT):

  • the most effective treatment for vasomotor symptoms;
  • women with a uterus need a progestin with estrogen to prevent endometrial hyperplasia and cancer;

benefit is greatest in women under 60 or within 10 years of menopause , at the lowest effective dose, reviewed yearly;

contraindications : breast or endometrial cancer, VTE , stroke or coronary disease, active liver disease and unexplained vaginal bleeding ;

the Women's Health Initiative found more breast cancer, stroke and VTE with combined therapy in older women;

vaginal estrogen treats local symptoms with minimal absorption.

Osteoporosis:

  • diagnosed by DXA T-score of -2.5 or less , or a fragility fracture;
  • prevented with calcium and vitamin D , weight-bearing exercise, no smoking and fall prevention;

treated with bisphosphonates : alendronate weekly, taken upright with water on an empty stomach because of esophagitis risk. Rare adverse effects are osteonecrosis of the jaw and atypical femoral fractures.

Alternatives include raloxifene (which raises VTE risk), denosumab and teriparatide.

Loading diagram... Postmenopausal Bleeding Diagnostic Pathway and FIGO PALM-COEIN Framework